Skip to main content
SpringerLink
Log in

Beeinflussung der Diabetesinzidenz durch Ramipril und Rosiglitazon

DREAM-Studie (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication)

Influence of diabetes incidence by ramipril and rosiglitazone

DREAM study (Diabetes reduction assessment with ramipril and rosiglitazone medication)

  • Klinische Studien
  • Published:
Der Internist Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Herder C, Peltonen M, Koenig W et al. (2006) Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 55: 2340–2346

    Article  PubMed  CAS  Google Scholar 

  2. Home PD et al. for the RECORD Study Group (2007) Rosiglitazone evaluated for cardiovaskular outcomes – An Interim Analysis. N Engl J Med 357: online v. 05.06.2007

    Article  Google Scholar 

  3. Nissen S, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: online v. 21.05.2007

    Google Scholar 

  4. Snitker S, Watanabe RM, Ani I et al. for the investigators of the Troglitazone in Prevention of Diabetes (TRIPOD) study (2004) Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 27: 1365–1368

    Article  PubMed  CAS  Google Scholar 

  5. Viberti G, Kahn SE, Greene DA et al. (2002) A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 25: 1737–1743

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der Autor weist auf seine Tätigkeit in den DSMBs der PROActive und Navigator Trials hin. Von ihm durchgeführte Studien wurden von Menarini, Novartis, NovoNordisk, Sanofi-Aventis und Servier unterstützt. Er erhielt Vortrags- und Konsultationshonorare von Bayer, GSK, Lilly, Menarini, Merck, Novartis, NovoNordisk, Rambaxi, Roche, Sanofi-Aventis, Seriver und Takeda.

Author information

Authors and Affiliations

  1. Institut für Diabetesforschung München an der GSF, Ingolstädter Landstraße 1, 85764, München-Neuherberg, Deutschland

    E. Standl

  2. Stuttgart, Deutschland

    S. Nitschmann

Authors
  1. E. Standl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Nitschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Standl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Standl, E., Nitschmann, S. Beeinflussung der Diabetesinzidenz durch Ramipril und Rosiglitazon. Internist 48, 1173–1176 (2007). https://doi.org/10.1007/s00108-007-1932-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-007-1932-8

Search

Navigation